Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

2

said support via covalent interactions.

1 (currently amended): A microarray comprising a support having a plurality of 1 2 discrete regions having a biopolymer spotted thereon, wherein chemoselectively attached-to said 3 biopolymer in each of said regions is a ligand that can be the same or different from a ligand in any other of said discrete regions, and wherein the concentration of said ligand in said discrete 4 5 regions is substantially normalized varies less than 50%. 2 (original): The microarray of claim 1, wherein said support is selected from the 1 2 group consisting of glass, polystyrene, PDVF membranes, nylon membranes, and polycarbonate 3 slides. 3 (original): The microarray of claim 1, wherein said biopolymer is a member 1 2 selected from the group consisting of oligosaccharides, proteins, polyketides, peptoids, 3 hydrogels, polylactates and polyurethanes. 4 (original): The microarray of claim 1, wherein said biopolymer is attached to 1 2 said support via noncovalent interactions. 1 5 (original): The microarray of claim 4, wherein said noncovalent interactions 2 are selected from the group consisting of hydrogen bonding, van der Waals interactions, 3 hydrophobic interactions, hydrophilic interactions and combinations thereof. 6 (original): The microarray of claim 1, wherein said biopolymer is attached to 1

1	7 (original): The microarray of claim 1, wherein said ligand is selected from the
2	group consisting of amino acids, peptides, proteins, sugars, lipids, nucleic acids, small organic
3	compounds, pharmaceutical agents, candidate pharmaceutical agents, natural or synthetic
4	antigens, and combinations thereof.
1	8 (canceled): The microarray of claim-1, wherein said ligand is attached to
2	said biopolymer via chemoselective ligation.
1	9 (original): The microarray of claim 1, wherein said biopolymer is agarose, and
2	said support is glass.
1	10 (withdrawn): The microarray of claim 1, wherein said biopolymer is human
2	serum albumin, and said support is polystyrene.
1	11 (canceled): The microarray of claim 1, wherein the concentration in said
2	discrete regions varies less than 50%.
1	12 (previously presented): The microarray of claim 1, wherein the concentration
2	in said discrete regions varies less than 20%.
1	13 (previously presented): The microarray of claim 1, wherein the concentration
2	in said discrete regions varies less than 5%.
1	14 (withdrawn): A method of producing a concentration-normalized ligand
2	array, said method comprising:
3	(a) forming a ligand-modified biopolymer by attaching a ligand to a
4	functionalized biopolymer via chemoselective ligation; and
5	(b) spotting an aliquot of said modified biopolymer mixture onto each of a
6	plurality of discrete regions on a solid support to produce a concentration-normalized ligand
7	array.

1 15 (withdrawn): The method of claim 14, wherein said method further 2 comprises, prior to step (b), the following step: (a)(i) combining said ligand-modified biopolymer with a biopolymer solution to 3 4 form a modified biopolymer mixture. 1 16 (withdrawn): The method of claim 14, wherein said solid support is selected 2 from the group consisting of glass, polystyrene, PDVF membranes, nylon membranes, and 3 polycarbonate slides. 1 17 (withdrawn): The method of claim 14, wherein said aliquot is spotted onto 2 said solid support under conditions sufficient to form a gel-coated surface. 1 18 (withdrawn): The method of claim 14, wherein said biopolymer is a member 2 selected from the group consisting of oligosaccharides, proteins, polyketides, peptoids, 3 hydrogels, polylactates and polyurethanes. 1 19 (withdrawn): The method of claim 14, wherein said ligand is selected from 2 the group consisting of amino acids, peptides, proteins, sugars, lipids, nucleic acids, small 3 organic compounds, pharmaceutical agents, candidate pharmaceutical agents and combinations 4 thereof. 1 20 (withdrawn): The method of claim 14, wherein said ligand-modified 2 biopolymer is peptide-modified agarose and said solid support is glass. 1 21 (withdrawn): The method of claim 14, wherein said ligand-modified 2 biopolymer is peptide-modified human serum albumin and said solid support is polystyrene. 1 22 (withdrawn): A method for promoting cell or tissue growth at a desired site, 2 said method comprising contacting said site with a ligand-modified biopolymer in an amount 3 effective to promote cellular chemotaxis and cell or tissue growth at said site, wherein said 4 biopolymer component is a member selected from the group consisting of agarose, polylysine

5

1

2

substantially normalized.

discrete regions made by

and polyacrylamide, wherein said ligand component is a chemotactic peptide specific for a cell 5 6 surface receptor, and wherein said ligand component is attached to said biopolymer component 7 via chemoselective ligation. 23 (withdrawn): The method of claim 22, wherein said biopolymer is agarose. 1 24 (withdrawn): The method of claim 22, wherein said site is a member selected 1 from the group consisting of a stent, a graft, an organ, a tissue and an implant. 2 25 (withdrawn): The method of claim 22, wherein said cell or tissue growth 1 2 occurs in vivo. 26 (withdrawn): The method of claim 22, wherein said cell or tissue growth 1 2 occurs in vitro. 27 (withdrawn): A method for assaying the binding of ligands to a binding 1 partner, said method comprising 2 (a) contacting a binding partner with a microarray of claim 1; and 3 (b) determining the amount of binding that occurs between said binding partner 4 5 and the ligands present in the discrete regions of said microarray. 28 (withdrawn): The method of claim 27, wherein said microarray comprises a 1 2 modified agarose biopolymer. 1 29 (currently amended): A microarray comprising a support having a plurality of discrete regions having a preformed ligand-modified biopolymer spotted thereon, wherein the 2 3 ligand can be the same or different from a ligand in any other of said discrete regions, and 4 wherein the concentration of said ligand in said discrete regions varies less than 50% is

30 (currently amended): A microarray comprising a support having a plurality of

<u>PATENT</u>

Appl. No. 10/815,468 Amdt. dated July 20, 2006 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1641

3	(a) forming a ligand-modified biopolymer by attaching a ligand to a
4	functionalized biopolymer via chemoselective ligation; and
5	(b) spotting an aliquot of said modified biopolymer mixture onto each of a
6	plurality of discrete regions on a solid support wherein said ligand can be the same or different
7	from a ligand in any other of said discrete regions, and wherein the concentration of said ligand
8	in said discrete regions varies less than 50% is substantially normalized.